TECELRA
STN: 125789
Proper Name: afamitresgene autoleucel
Tradename: TECELRA
Manufacturer: Adaptimmune LLC
Indication:
- Treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared Companion Diagnostic devices.
Product Information
Supporting Documents
- August 1, 2024 Approval Letter - TECELRA
- August 1, 2024 Summary Basis for Regulatory Action - TECELRA
- Approval History, Letters, Reviews, and Related Documents - TECELRA